US2006217310A1PendingUtilityA1

Fibroblast growth factor 1 (FGF-1) used for skin care

56
Assignee: CHIU ING-MINGPriority: Aug 17, 2004Filed: Mar 23, 2006Published: Sep 28, 2006
Est. expiryAug 17, 2024(expired)· nominal 20-yr term from priority
Inventors:Ing-Ming ChiuToko Wen
A61P 29/00C07D 207/444C07D 207/46C07D 307/34
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided are compositions comprising a fibroblast growth factor 1 (FGF-1) for skin care, and methods of use of such compositions. The FGF-1 is constructed into a recombinant expression vector, and characterized by the molecular characteristics. The FGF-1 can modulate mitogenic activities and mediate both the FGF-2 and KGF signaling pathway that can promote proliferation of fibroblast cells and epidermal cells. A mutant FGF-1 has the longer half life than wild type has in virtue of its capabilities of anti-oxidization or no further proteolytic degradation.

Claims

exact text as granted — not AI-modified
1 . A composition for promoting proliferation of fibroblast cells or epidermal cells comprising an effective amount of a fibroblast growth factor 1 (FGF-1).  
     
     
         2 . The composition of  claim 1 , wherein the FGF-1 is human FGF-1 (hFGF-1).  
     
     
         3 . The composition of  claim 2 , wherein the hFGF-1 is selected from the group consisting of wild type hFGF-1, recombinant hFGF-1, mutant hFGF-1, and derivatives thereof.  
     
     
         4 . The composition of  claim 3 , wherein the wild type hFGF-1 has the amino acid sequence shown in SEQ ID NO: 1.  
     
     
         5 . The composition of  claim 3 , wherein the hFGF-1 has the amino acid sequence shown in SEQ ID NO: 2.  
     
     
         6 . The composition of  claim 3 , wherein the hFGF-1 has the amino acid sequence shown in SEQ ID NO: 3.  
     
     
         7 . The composition of  claim 2 , wherein the hFGF-1 is characterized by a molecular weight of about 17.3 kDa when analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis under reducing conditions.  
     
     
         8 . The composition of  claim 1 , wherein the FGF-1 modulates the mitogenic activities of fibroblast cells.  
     
     
         9 . The composition of  claim 1 , wherein the FGF-1 stimulates the basic fibroblast growth factor signaling pathway to promote proliferation of fibroblast cells.  
     
     
         10 . The composition of  claim 1 , wherein the FGF-1 stimulates the keratinocyte growth factor signaling pathway to promote proliferation of epidermal cells.  
     
     
         11 . The composition of  claim 1 , which applies to skin care products.  
     
     
         12 . The composition of  claim 11 , wherein the skin care products comprises collagen.  
     
     
         13 . The composition of  claim 11 , wherein the products have skin cells regeneration, stimulation of collagen synthesis, wrinkle elimination, senescence decrease, skin elasticity maintenance, wound healing, or vascularization.  
     
     
         14 . The composition of  claim 11 , wherein the product further comprises a cosmetically or pharmaceutically acceptable carrier.  
     
     
         15 . The composition of  claim 11 , wherein the product type comprises lotion, cream, mask, gel, emulsion, balsam, ointment, liquid, powder, or other types of topically or internally applicable material.  
     
     
         16 . The composition of  claim 13 , wherein the product is administered to intact skin, burn, scalding, or wound.  
     
     
         17 . The composition of  claim 1 , wherein the hFGF-1 is produced by the method comprising (a) producing a recombinant vector comprising hFGF-1 gene, (b) preparing a host cell for expressing the recombinant vector, and (c) purifying the hFGF-1 from the host cell culture.  
     
     
         18 . The composition of  claim 17 , wherein the recombinant vector is selected from a group consisting of plasmid, virus and phage vector.  
     
     
         19 . The composition of  claim 17 , wherein the host cell is selected from a group consisting of bacteria, yeast, insect cell, or mammalian cell.  
     
     
         20 . A polypeptide for hFGF-1 comprises an amino acid sequence shown in SEQ ID NO: 4 or derivatives thereof.  
     
     
         21 . The polypeptide of  claim 20 , which represents longer half-life than wild type hFGF-1 as shown in SEQ ID NO: 1.  
     
     
         22 . The composition of  claim 3 , wherein the hFGF-1 has the amino acid sequence shown in SEQ ID NO: 4.

Join the waitlist — get patent alerts

Track US2006217310A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.